Infusion Therapies & Technologies was Baxter International’s largest product and service line in fiscal 2025, bringing in $4.10B of $11.24B (36%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Infusion Therapies & Technologies | $3.82B | $3.96B | $4.10B | $4.10B | ||||||
| Chronic Therapies | — | — | — | — | ||||||
| Renal Care | — | — | — | — | ||||||
| Renal | — | — | — | — | ||||||
| Medication Delivery | — | — | — | — | ||||||
| Pharmaceuticals | — | — | — | — | ||||||
| Care & Connectivity Solutions | $1.79B | $1.80B | $1.81B | $1.91B | ||||||
| Injectables & Anesthesia | $1.31B | $1.35B | $1.37B | $1.35B | ||||||
| Drug Compounding | $821.00M | $902.00M | $1.04B | $1.14B | ||||||
| Front Line Care | $1.15B | $1.21B | $1.14B | $1.16B | ||||||
| Advanced Surgery | $998.00M | $1.05B | $1.10B | $1.20B | ||||||
| Clinical Nutrition | — | — | — | — | ||||||
| Nutrition | — | — | — | — | ||||||
| Acute Therapies | — | — | — | — | ||||||
| Biopharma Solutions | — | — | — | — | ||||||
| Other | $177.00M | $87.00M | $67.00M | $381.00M | ||||||
| Total | $10.06B | $10.36B | $10.64B | $11.24B |
Baxter International brought in $11.24B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 5.7% from $10.64B in fiscal 2024. Infusion Therapies & Technologies was the largest at $4.10B (36.5%), ahead of Care & Connectivity Solutions at $1.91B (17.0%) and Injectables & Anesthesia at $1.35B (12.0%). The other four lines brought in $3.88B combined.
Compared with fiscal 2024, Other grew fastest, up 468.7% to $381.00M, while Injectables & Anesthesia fell the most, down 1.5% to $1.35B. From fiscal 2022 to 2025, combined revenue from these lines grew from $10.06B to $11.24B, a compound annual growth rate of 3.8%. Infusion Therapies & Technologies' share of the total fell from 38.0% to 36.5%.
Medical Products & Therapies was Baxter International’s largest segment in fiscal 2025, bringing in $5.30B of $11.24B (47%).
| Segment | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products | — | — | — | — | |||||||||||
| Hospital Products | — | — | — | — | |||||||||||
| Americas | — | — | — | — | |||||||||||
| Bioscience | — | — | — | — | |||||||||||
| Bio Science | — | — | — | — | |||||||||||
| Medical Products & Therapies | $4.82B | $5.01B | $5.21B | $5.30B | |||||||||||
| Kidney Care | — | — | — | — | |||||||||||
| Renal | — | — | — | — | |||||||||||
| Emea | — | — | — | — | |||||||||||
| Healthcare Systems & Technologies | $2.94B | $3.01B | $2.95B | $3.07B | |||||||||||
| Apac | — | — | — | — | |||||||||||
| Pharmaceuticals | $2.13B | $2.25B | $2.41B | $2.49B | |||||||||||
| Other | $177.00M | $87.00M | $67.00M | $381.00M | |||||||||||
| Business Segment Other | — | — | — | — | |||||||||||
| Total | $10.06B | $10.36B | $10.64B | $11.24B |
Baxter International brought in $11.24B from its four segments in fiscal 2025, the year ended December 31, 2025. That was up 5.7% from $10.64B in fiscal 2024. Medical Products & Therapies was the largest at $5.30B (47.1%), ahead of Healthcare Systems & Technologies at $3.07B (27.3%) and Pharmaceuticals at $2.49B (22.2%). The remaining segment, Other, brought in $381.00M.
Compared with fiscal 2024, Other grew fastest, up 468.7% to $381.00M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $10.06B to $11.24B, a compound annual growth rate of 3.8%. Medical Products & Therapies' share of the total fell from 47.9% to 47.1%.
United States was Baxter International’s largest region in fiscal 2025, bringing in $6.12B of $11.24B (54%).
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.77B | $5.74B | $5.85B | $6.12B | ||||||||||||||
| U.S | — | — | — | — | ||||||||||||||
| U.S. & Puerto Rico Plans | — | — | — | — | ||||||||||||||
| Americas | — | — | — | — | ||||||||||||||
| Us | — | — | — | — | ||||||||||||||
| U S | — | — | — | — | ||||||||||||||
| Consolidated Net Sales | — | — | — | — | ||||||||||||||
| Non-Us | — | $4.54B | — | — | ||||||||||||||
| Europe | — | — | — | — | ||||||||||||||
| Rest Of World | $3.04B | — | $3.44B | $3.73B | ||||||||||||||
| Emea | — | — | — | — | ||||||||||||||
| Apac | — | — | — | — | ||||||||||||||
| Asia Pacific | — | — | — | — | ||||||||||||||
| Asia-Pacific | — | — | — | — | ||||||||||||||
| Emerging Markets | $1.25B | — | $1.35B | $1.39B | ||||||||||||||
| Latin America & Canada | — | — | — | — | ||||||||||||||
| Other | — | $87.00M | — | — | ||||||||||||||
| Total | $10.06B | $10.36B | $10.64B | $11.24B |
Baxter International brought in $11.24B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 5.7% from $10.64B in fiscal 2024. United States was the largest at $6.12B (54.4%), ahead of Rest Of World at $3.73B (33.2%) and Emerging Markets at $1.39B (12.4%).
Compared with fiscal 2024, Rest Of World grew fastest, up 8.5% to $3.73B. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $10.06B to $11.24B, a compound annual growth rate of 3.8%. United States' share of the total fell from 57.4% to 54.4%.
Baxter International stopped reporting Non-Us ($4.54B in fiscal 2023) and Other ($87.00M in fiscal 2023) as separate regions.
Baxter International (BAX) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Infusion Therapies & Technologies was its largest product and service line, bringing in $4.10B (36.5% of the total), followed by Care & Connectivity Solutions at $1.91B (17.0%).
Infusion Therapies & Technologies was Baxter International's largest product and service line in fiscal 2025, bringing in $4.10B, or 36.5% of the $11.24B total across its seven product and service lines.
Medical Products & Therapies was Baxter International's largest segment in fiscal 2025, bringing in $5.30B, or 47.1% of the $11.24B total across its four segments.
United States was Baxter International's largest region in fiscal 2025, bringing in $6.12B, or 54.4% of the $11.24B total across its three regions.
Among Baxter International's product and service lines that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 468.7% from $67.00M to $381.00M.
Every figure comes from Baxter International's annual financial filings, as reported. Each line keeps the name Baxter International gives it, and years follow its fiscal calendar.
Baxter International's revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.